Beclamide (original) (raw)
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Beclamide
 |
|
|---|---|
| Clinical data | |
| Routes of administration | By mouth |
| ATC code | N03AX30 (WHO) |
| Legal status | |
| Legal status | BR: Class C1 (Other controlled substances)[1] |
| Identifiers | |
| IUPAC name _N_-Benzyl-3-chloropropanamide | |
| CAS Number | 501-68-8  Y |
| PubChem CID | 10391 |
| ChemSpider | 9962 Y |
| UNII | F5N0ALI65V |
| KEGG | D07300 Y |
| ChEMBL | ChEMBL64195 Y |
| CompTox Dashboard (EPA) | DTXSID5057755  |
| ECHA InfoCard | 100.007.207 |
| Chemical and physical data | |
| Formula | C10H12ClNO |
| Molar mass | 197.66 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| Melting point | 94 °C (201 °F) |
| SMILES ClCCC(=O)NCc1ccccc1 | |
| InChI InChI=1S/C10H12ClNO/c11-7-6-10(13)12-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,13) YKey:JPYQFYIEOUVJDU-UHFFFAOYSA-N Y |
|
| (verify) |
Beclamide (marketed as Chloracon, Hibicon, Posedrine, Nydrane, Seclar, and other names) is a drug that possesses anticonvulsant activity.[2] It is no longer used.
It has been used as a sedative and as an anticonvulsant.
It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures.
Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia.[3]
Side effects are uncommon but include stomach pain, nervousness, giddiness, skin rash and leukopenia. It is counter-indicated in breast feeding as it is passed in the milk.
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP (October 1995). "Metabolism of beclamide after a single oral dose in man: quantitative studies". The Journal of Pharmacy and Pharmacology. 47 (10): 876–8. doi:10.1111/j.2042-7158.1995.tb05757.x. PMID 8583359. S2CID 19556266.
- ^ Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM (February 1990). "Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide". Acta Psychiatrica Scandinavica. 81 (2): 162–7. doi:10.1111/j.1600-0447.1990.tb06472.x. PMID 2183543. S2CID 26772370.
- The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.